secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2022-07-15T23:59:59+00:00
Accession:  0001628280-22-018937
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia and CCO Max Colao mutually agree to separation effective July 22
------------------------------------------------------------------------

- Max Colao, Chief Commercial Officer, will cease employment on July 22, 2022 by mutual agreement.
- Severance includes 12 months base salary ($488,835) plus eligibility for performance bonus (target $244,418).
- COBRA benefits for up to 12 months if elected.
- No replacement named; separation agreement expected to mirror existing employment terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022018937/0001628280-22-018937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000162828022018937/auph-20220715.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-018937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer